Stem Cells to the Rescue

I have been involved with Hadassah, the Women’s Zionist Organization of America for years.  I have visited the hospital in Jerusalem numerous times and even saw the head of Neurology, Prof. Tamir Ben-Hur, as a patient.  The stem cell research in Israel is far ahead of what we are doing here in the United States and in other countries.  Just last month, a break-through was made in ALS research.

New protocols for transplanting stem-cells are the key to this research.

This is an image of stem cells being turned into brain cells affected by Parkinson’s.Credit: Parkinson’s UK 

Here is the latest news on Parkinson’s Disease research from Hadassah which is also looking at these protocols.

February 2016
From Treating Symptoms to Restoring Health: Parkinson’s Progress at Hadassah

With the long-term goal of replacing lost neurons and restoring function permanently to patients with Parkinson’s disease, Hadassah Medical Center physician/researchers in the Human Embryonic Stem Cell Center are uncovering crucial factors that affect the success of stem cell therapy.

In Parkinson’s disease, progressive degeneration and loss of dopamine-producing neurons in the mid-brain cause motor and cognitive deficits, since dopamine is  essential to the normal functioning of the central nervous system. Whereas current treatment for Parkinson’s disease can only alleviate symptoms, regenerative therapy using stem cells targets the production of new dopamine.
As Prof. Benjamin Reubinoff, head of the Stem Cell Center, explains: “To be able to produce a reasonable number of dopaminergic neurons from human embryonic stem cells, there is a need to refine some previously described protocols for directing the cells to differentiate.”

One of the factors Hadassah’s researchers are investigating is how the extracellular environment affects the process of differentiation. The culture plates, Prof. Reubinoff brings out, “provide an environment which is profoundly different from that of the intact soft tissue of the brain.” With this in mind, Dr. Sharona Even Ram from the Stem Cell Center developed a method to grow cells in modified 3D soft culture conditions and compared the results to those achieved using the hard plastic plates. Subsequently, they followed changes on the cellular and molecular level along the differentiation process. “Indeed we found that soft and hard substrates have different capacity of supporting neuronal maturation,” reports Prof. Reubinoff.

Another challenge that scientists face in the stem cell differentiation process in culture (in vitro) is that some of the cells retain what is called their “stemness.”  In other words, they fail to mature, but at the same time they show high proliferation rates. These cells bear the risk of forming tumors after transplantation, which has been seen worldwide in animal models. Therefore, Prof. Reubinoff and Dr. Even Ram are investigating techniques to “clean the culture,” eliminating these cells before transplantation takes place.
Having characterized the changes in cell components that normally occur as stem cells differentiate, the researchers are able to identify specific elements that mature cells carry which endow them with increased resistance to toxic agents. They found that immature proliferating cells do not contain these elements, and therefore can be eliminated by specific toxic agents. One of the methods they are using, Prof. Reubinoff reports, has been recently patented in the United States.

A third issue that Hadassah researchers have tackled is the enhancement of the neuron’s survival once it has been transplanted to the host tissue.
A challenge in this step is that the compromised brain of the Parkinson’s patient may not provide a hospitable environment for the newly transplanted cells. To deal with this issue, they are working toward supplying extracellular materials that will enable the cells to attach to the host and survive, long-term. Prof. Reubinoff reports that Hadassah’s team is collaborating with a group from Tokyo, Japan to test materials for their ability to support neuronal growth and maturation, such as laminin peptides. They are also involved in a joint exploration with a group from Nottingham, United Kingdom to test biodegradable micro-particles as a cell delivery method, which would facilitate a slow release of growth factors–here again enhancing the cell’s survival potential. This is being tested in culture and in an animal model.

While there are clearly hurdles to overcome in ensuring the success of regenerative therapy for Parkinson’s disease, stem cells hold great promise for a transformation from treating symptoms to restoring health.

News you can use about Stem Cells:

For more information on stem-cell research for Parkinson’s Disease, ALS and other neurological disorders at Hadassah, go to

You can view Prof. Ben Hur’s TED Talk on Stem Cells here:  Stem cells — protectors of the brain

From Science Daily, new stem cell research offers up new clues as to how Parkinson’s spreads from cell to cell:…016/02/160218132257.htm


An Important Breakthough for ALS

“In the clinical trial of intrathecal infusion of stem cells there were no major adverse effects, and close to 90% of patients showed slowing in the progression of disease, as measured by their respiratory function or their general motor disability”
—Principal Investigator Dr. Dimitrios Karussis, MD, PhD, Sr. Neurologist, HMO Neurology


First, I want to thank all of you who have been following me for the last 10 months.  You helped me reach the magic number of 100 followers!!!  Thank you for all of your support in the last year.  It has been an exciting experience for me watching how the internet brings us all so much closer.  This blog has been read in countries all over the world and several of the posts have been re-posted on other sites.  I am looking forward to sharing my thoughts and news about Parkinson’s Disease with you again this year.

Second, and more important, as a past president of Hadassah Southern California and a member of the Hadassah National Board, I am proud to share the following news with you.  Hadassah, The Women’s Zionist Organization of America announced yesterday that a new ALS treatment utilizing a stem cell infusion protocol performed at Hadassah Medical Organization (HMO) and developed by the US/Israeli biotech company BrainStorm Cell Therapeutics (NASDAQ: BCLI), has significantly slowed the progression of Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s Disease).  For the full text, click here.

This treatment has the potential to be used for other neurological disorders, such as Parkinson’s Disease and MS.  Israel has long been in the forefront of stem-cell research since its inception and there has been much hope for a breakthrough in Parkinson’s research ever since.  I have actually been seen at Hadassah Hospital in Jerusalem twice by the head of Neurology, Professor Tamir Ben-Hur.  When I last saw him three years ago, he had nothing new to report about stem-cell treatment for PD.  Delivery of stem-cells was the big issue.  At the time,  they were trying to inject stem cells directly into the brain, but unfortunately, most did not survive the transplant.  With this new treatment, there is more hope for the future.

On Thursday, I will have the privilege of meeting with Dr. Dimitrios Karussis, MD, PhD, Sr.

Neurologist, HMO Neurology, who is the principal investigator in the study.  I have so many questions for him and I hope to be able to share more news with you after our meeting.

Watch Monday’s press conference